Zim Laboratories Limited has informed the Exchange about earnings presentation for Q4 & FY26
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ZIM Laboratories reported FY26 total operating income of ₹3,744 Mn (down 1.2% YoY) with EBITDA of ₹414 Mn (down 16.4%) and EBITDA margin at 11.1% versus 13.1% in FY25. Q4FY26 revenue was ₹1,053 Mn (down 3.2% YoY) with EBITDA margin at 12.7% (down 230 bps). PAT declined 52% to ₹58 Mn. The company attributed margin pressure to geopolitical issues in the Middle East, raw material and employee cost inflation, and a failed EU GMP audit in July 2025 that delayed NIP product launches. On a positive note, 57 regulatory filings were submitted and 34 Marketing Authorizations received in FY26, including MA for Dabigatran Etexilate in Europe. The company raised ₹35 crore via preferential issue to Florintree Trinex LLP. R&D investment was sustained at 8.3% of operating income.
The significant decline in profitability and margin compression reflects operational headwinds from the MENA war situation and cost pressures. The successful regulatory filings and new product launches (particularly in EU) provide a pipeline for future recovery. The ₹35 crore capital raise strengthens the balance sheet.